Unknown

Dataset Information

0

Discovery of the Selective CYP17A1 Lyase Inhibitor BMS-351 for the Treatment of Prostate Cancer.

ABSTRACT: Efforts to identify a potent, reversible, nonsteroidal CYP17A1 lyase inhibitor with good selectivity over CYP17A1 hydroxylase and CYPs 11B1 and 21A2 for the treatment of castration-resistant prostate cancer (CRPC) culminated in the discovery of BMS-351 (compound 18), a pyridyl biaryl benzimidazole with an excellent in vivo profile. Biological evaluation of BMS-351 at a dose of 1.5 mg in castrated cynomolgus monkeys revealed a remarkable reduction in testosterone levels with minimal glucocorticoid and mineralcorticoid perturbation. Based on a favorable profile, BMS-351 was selected as a candidate for further preclinical evaluation.

SUBMITTER: Huang A 

PROVIDER: S-EPMC4716597 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Efforts to identify a potent, reversible, nonsteroidal CYP17A1 lyase inhibitor with good selectivity over CYP17A1 hydroxylase and CYPs 11B1 and 21A2 for the treatment of castration-resistant prostate cancer (CRPC) culminated in the discovery of BMS-351 (compound 18), a pyridyl biaryl benzimidazole with an excellent in vivo profile. Biological evaluation of BMS-351 at a dose of 1.5 mg in castrated cynomolgus monkeys revealed a remarkable reduction in testosterone levels with minimal glucocorticoi  ...[more]

Similar Datasets

Unknown Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms.
| S-EPMC4538448 | biostudies-literature
Unknown Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
| S-EPMC4538445 | biostudies-literature
Unknown Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable γ-Secretase Inhibitor.
| S-EPMC4007960 | biostudies-literature
Unknown Y08060: A Selective BET Inhibitor for Treatment of Prostate Cancer.
| S-EPMC5846130 | biostudies-literature
Unknown The role of PI3K/AKT-related PIP5K1? and the discovery of its selective inhibitor for treatment of advanced prostate cancer.
| S-EPMC4156761 | biostudies-literature
Unknown Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment.
| S-EPMC7993727 | biostudies-literature
Unknown Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGF?R1 Inhibitor as an Immuno-oncology Agent.
| S-EPMC7025382 | biostudies-literature
Unknown CYP17A1 inhibitors in castration-resistant prostate cancer.
| S-EPMC4323677 | biostudies-literature
Unknown Targeting of CYP17A1 Lyase by VT-464 Inhibits Adrenal and Intratumoral Androgen Biosynthesis and Tumor Growth of Castration Resistant Prostate Cancer.
| S-EPMC5066251 | biostudies-literature
Unknown Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPAR? Selective Agonist.
| S-EPMC4904259 | biostudies-literature